{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062020","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.702652+00:00","generated_at":"2026-06-08T06:16:32.776493+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma reports Q3 2023 cash of $105.6M; Phase 3 sarcoidosis study enrollment to complete early Q2 2024","bullets":["Cash, cash equivalents and investments totaled $105.6M as of September 30, 2023.","Phase 3 EFZO-FIT study in pulmonary sarcoidosis expects enrollment completion early Q2 2024; positive DSMB safety review.","Phase 2 EFZO-CONNECT study in systemic sclerosis-ILD dosed first patient.","R&D expenses were $10.3M, G&A $2.6M, collaboration revenue $0.4M from Kyorin agreement.","Updated cash runway guidance: sufficient through BLA filing for efzofitimod in sarcoidosis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062020","json":"https://secwatch.observer/filing/0000950170-23-062020.json","markdown":"https://secwatch.observer/filing/0000950170-23-062020.md","text":"https://secwatch.observer/filing/0000950170-23-062020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023062020/0000950170-23-062020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023062020/life-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:16:32.776493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e4e851f38400fd777cc5fcd4cc70e659e3ca9ce","claim":"aTYR PHARMA INC updated its third quarter of 2023 guidance (reaffirmed).","evidence_excerpt":"On November 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023062020/0000950170-23-062020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}